Last update 07 Oct 2025

Sotorasib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
索托雷塞, 索拖拉西布, AMG 510
+ [6]
Target
Action
inhibitors
Mechanism
KRAS G12C inhibitors(GTPase KRas G12C inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (28 May 2021),
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Breakthrough Therapy (China), Orphan Drug (South Korea), Orphan Drug (Australia), Conditional marketing approval (United States), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC30H30F2N6O3
InChIKeyNXQKSXLFSAEQCZ-UHFFFAOYSA-N
CAS Registry2296729-00-3

External Link

KEGGWikiATCDrug Bank
-Sotorasib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
KRAS G12C mutant Colorectal Cancer
United States
16 Jan 2025
KRAS G12C mutant Non-small Cell Lung Cancer
United States
28 May 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Small Cell Lung CancerPhase 3
United States
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
China
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
Japan
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
Argentina
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
Australia
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
Austria
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
Belgium
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
Brazil
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
Bulgaria
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
Canada
16 Nov 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
squamous cell lung carcinoma
First line
KRAS G12C mutation
52
Sotorasib+Platinum containing dual drug chemotherapy+bevacizumab
qeinnvmaai(gbangfopan) = qshrijandl llkwfmwmfn (wngcfqplal )
Positive
08 Sep 2025
Sotorasib+Platinum containing dual drug chemotherapy+bevacizumab
(PD-L1 ≥50%)
qeinnvmaai(gbangfopan) = kyrbdmjqpt llkwfmwmfn (wngcfqplal )
NEWS
ManualManual
Phase 2
-
okjyevuebl(pyubwwoczs) = ssndmpwtax djwgdkuspp (zbofizcoeh )
Positive
16 Jul 2025
okjyevuebl(pyubwwoczs) = avucfunypl djwgdkuspp (zbofizcoeh )
Phase 3
KRAS G12C mutant Colorectal Cancer
TP53 | DNMT3A | ERBB2 ...
99
nfnwdhybkz(wmhdarbmkf) = fktqwcmfjx wxpidgheqp (hzsuipwzci )
Positive
30 May 2025
nfnwdhybkz(wmhdarbmkf) = ttpokdakbe wxpidgheqp (hzsuipwzci )
Phase 1
40
Sotorasib plus Panitumumab plus FOLFIRI
clicnlwsyn(hegttbkqpw) = surwiocfyp rrebcvtlax (ydwdfkeeyl, 7.0 - 10.8)
Positive
30 May 2025
Phase 2
118
(TP53 CO-MUT)
umszmlcaha(gilkxwicey) = ihovrmmpmk xeicoaxhbu (aovdqegocr, 23 - 47)
Positive
30 May 2025
(STK11 CO-MUT)
umszmlcaha(gilkxwicey) = ovnmwxjrhn xeicoaxhbu (aovdqegocr, 4 - 28)
Not Applicable
4,510
ypqbfnoqlb(fpgheyvjiq) = zzyqjboyse vliwphjvmj (tfksojvuvh, 28% - 36)
Negative
30 May 2025
ypqbfnoqlb(fpgheyvjiq) = kmrtmeaqsp vliwphjvmj (tfksojvuvh, 19% - 34)
Phase 3
160
jstdxsrwif(getxxnwjsh) = cgzormjtlg mzvfwaahwd (mvpxzgjymz )
Positive
07 May 2025
jstdxsrwif(getxxnwjsh) = fyuwpkymkc mzvfwaahwd (mvpxzgjymz )
Phase 3
107
sifokbnjmd(lwlgeyszsc) = xwxpyovryu yolllmwbkf (hkygzqesor, 4.2 - 6.3)
Positive
16 Jan 2025
sifokbnjmd(lwlgeyszsc) = sbvxvsxlau yolllmwbkf (hkygzqesor, 1.9 - 3.9)
Phase 1/2
3
Defactinib,Avutometinib, sotorasib
hcifefxlld(saikcryuma) = None byrzypvlbq (ohovqwvjhr )
Positive
18 Dec 2024
Phase 1
KRAS G12C mutant Colorectal Cancer
First line
KRAS G12C–mutated
40
ouantqdnda(xhwzbopwlc) = jdawkffzvy ohjzwvaxxa (krnyzgxqmt )
Positive
15 Sep 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free